Supported Innovations

 

MedMinEHR- Cloud Search any EMR

 

For pharma, med device, clinical trial and lab services organizations finding an eligible patient at a practice site is a costly and time consuming task.  Practice staff do not have the time or experience in searching their own EMRs.

MedminEHR is a cloud based EMR search service for the sales and support teams of pharmaceutical, medical device, research and lab services organizations.  MedminEHR equips teams with the means to extract value from the medical record, drive immediate impact, and provide clinicians with actionable insights.

MedminEHR’s proprietary electronic search integrates with most EMR and other third Party Administrators. MedminEHR offers its clients a complete solution, with faster turnaround times and more reliable and accurate results, in a manner that is safe, secure and HIPAA-compliant in all respects.

MedminEHR allows sales teams and CROs to leverage what is hidden in client EMRs.  With MedminEHR they can:

  • Identify eligible or at-risk patients

  • Drive product value for physicians and patients

  • Reveal unknown cases and new correlations

  • Maximize the efficiency of site visits

“My doctors always ask me who is eligible based on ejection fraction.  This tool helps them identify the eligible patients with no error.”

— Cardiac Implantable Device Rep

 
 

Personalized Drug Trial Programs Using Genome and Cardiac Marker

The Cardiac Safety Research Consortium (CSRC) was created on the basis of the principles of US Food and Drug Administration's (FDA's) Critical Path Initiative to facilitate collaborations among academicians, industry professionals, and regulators to develop consensus approaches addressing cardiac and vascular safety issues that can arise in the development of new medical products.

Today, current post-market drugs are going back into clinical trials to re-evaluate their cardiovascular impact. 

Like Minded Strategy Group is creating a consortium to introduce new innovative methods of monitoring cardiovascular impact. 

 

Joining the group are a genomics lab and a cardiovascular diagnostics company deploying cloud based machine learning and AI to improve upon the understanding or cardiac load.

The new data and analysis created will inform drug trials on the pharmacogenomic impact of a drug, any genetic markers that increase risk for cardiovascular disease, Cardiac disease risk based on a new FDA Cleared algorithm that bests 12-Lead ECG, Echo and Stress test combined- via a simple 10 minute test that can be done at home.

The data being collected and analyzed will be stored in blockchain for secure access to pharmaceutical manufacturers in real time.